Real-Time Trade Update: New Gold Inc. (USA) (NGD), St. Jude Medical ( STJ)

0
357

New Gold Inc. (USA) (NYSEMKT:NGD)

Stock’s Trading Stats:

New Gold Inc. (USA) (NYSEMKT:NGD) is trading down with a percentage change of -0.43% and is at $4.68 right now. The Company’s market capitalization stands at $2.50 Billion in the current trading Session whereas, its outstanding shares are 510.06 Million.

Recent Press Release:

New Gold Inc. (USA) (NGD) on April 28, 2016 declared the voting results from the election of its Board of Directors at New Gold’s Annual General Meeting of Shareholders (the “Meeting”) held on April 27, 2016 in Toronto, Ontario.  The director nominees listed in the Administration Information Circular dated March 4, 2016 were elected as directors of New Gold at the Meeting.

New Gold is an intermediate gold mining company. The company has a portfolio of four producing assets and two noteworthydevelopment projects. The New Afton Mine in Canada, the Mesquite Mine in the United States, the Peak Mines in Australia and the Cerro San Pedro Mine in Mexico, provide the company with its current production base. In addition, New Gold owns 100% of the Rainy River and Blackwater projects, both in Canada, in addition to a 4% gold stream on the El Morro project located in Chile.

St. Jude Medical, Inc.(NYSE:STJ)

Stock’s Trading Stats:

St. Jude Medical, Inc. (NYSE:STJ) is declining -0.14% percent and is at $76.09 in the Real-Time trading session. The stock’s market capitalization stands at $21.14 Billion with outstanding shares of 283.45 Million.

Recent Press Release:

St. Jude Medical, Inc. (STJ) on April 28, 2016 declared new, two-year data from the ROADMAP (Risk Assessment and Comparative Effectiveness Of Left Ventricular Assist Device and Medical Administration in Ambulatory Heart FailurePatients) Clinical Study. Two-year study results were presented recently during the International Society for Heart and Lung Transplantation (ISHLT) 36TH Annual Meeting and Scientific Sessions. The study met its primary endpoint of improved survival with improved functional status at 24 months in patients implanted with the HeartMate II left ventricular assist device (LVAD) contrast to optimal medical administration (OMM) highlighting the benefit of the HeartMate II LVAD. Furthermore, survival with improved functional status, quality of life (as measured by EQ-5D Visual Analog Scale), and reduced severity of depression with HeartMate II LVAD contrast to OMM at two years.

The ROADMAP study was a prospective, multi-center observational study of 200 patients that evaluated the effectiveness of the HeartMate II LVAD contrast to OMM in a patient population not dependent on inotropic medications (medications that alter the force of muscular contractions).

Seventy percent of the HeartMate II LVAD patients survived at two years, contrast with 41 percent of those treated with medications alone (medically managed patients) on an as-treated basis. At two years of follow-up, 30 percent of patients in the HeartMate II LVAD group as compared to 12 percent of patients on OMM, met the primary endpoint of survival on the original therapy together with a 75 meter increase in six minute walk test distance (6MWD), a difference, which was statistically noteworthy (p=0.012). These benefits were apparent even though the LVAD cohort was more severely ill, with 65 percent of HeartMate II LVAD patients contrast with just 34 percent in the medical administration group designated as INTERMACS profile 4 at baseline.